Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Accretive Health, Inc.    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Accretive Health, Inc. : Accretive Health Reports Inducement Grant under NYSE Rule 303A.08

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2013 | 01:05pm CET

Accretive Health, Inc. (NYSE: AH) today announced that pursuant to the employment agreement entered into with Stephen Schuckenbrock on April 2, 2013, the company granted to Mr. Schuckenbrock on April 3, 2013 a non-qualified stock option under the New York Stock Exchange inducement grant exception. The inducement grant was approved by the company's Board of Directors on April 1, 2013 and is being made as an inducement material to Mr. Schuckenbrock's acceptance of employment with the company, in accordance with New York Stock Exchange Rule 303A.08. The company previously announced that Mr. Schuckenbrock has been appointed President and Chief Executive Officer and a member of the company's Board of Directors, effective April 3, 2013.

The stock option is for the purchase of 2,903,801 shares of the company's common stock, with an exercise price of $9.56, which was the closing price of the company's common stock reported on the New York Stock Exchange on April 3, 2013. The stock option will vest and become exercisable on a ratable monthly basis over 48 months based on continued service to the company, subject to acceleration in specified circumstances.

Accretive Health is providing the above information regarding Mr. Schuckenbrock's inducement grant in accordance with New York Stock Exchange Rule 303A.08.

About Accretive Health

At Accretive Health, our mission is to help our healthcare clients strengthen their financial stability and deliver better care at a more affordable cost to the communities they serve (increasing healthcare access to all). For more information, visit www.accretivehealth.com.

Accretive Health, Inc.
Investor Relations:
Atif Rahim
Telephone: 312.324.5476
email: investorrelations@accretivehealth.com
or
Media:
Puneet Singh
Telephone: 330.565.6802
email: mediarelations@accretivehealth.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACCRETIVE HEALTH, INC.
12/05 ACCRETIVE HEALTH : Levels in Review for Accretive Health, Inc.
11/02 ACCRETIVE HEALTH, INC. : Results of Operations and Financial Condition, Financia..
11/02 ACCRETIVE HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
11/02 Accretive Health Reports Third Quarter 2016 Results
10/19 Accretive Health to Release Third Quarter 2016 Results on November 2
10/05 ACCRETIVE HEALTH, INC. : Entry into a Material Definitive Agreement, Financial S..
09/28 ACCRETIVE HEALTH, INC. : Regulation FD Disclosure, Financial Statements and Exhi..
09/16 ACCRETIVE HEALTH, INC. : Other Events (form 8-K)
09/09 ACCRETIVE HEALTH, INC. : Entry into a Material Definitive Agreement, Financial S..
08/04 ACCRETIVE HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
More news
Sector news : Ambulance & Emergency Services
12/05 CAMBIAN : UK health firm Cambian to sell adult services unit for 377 mln stg
11/24DJIHH HEALTHCARE BHD : Malaysia's IHH Healthcare 3Q Net Profit Up 46%
11/18 Synlab ready to snap up more lab chains after debt deal
11/16 South Africa's Life Healthcare to buy controlling stake in Britain's Alliance..
11/09 Pharma, biotech shares soar as Trump win calms pricing talk
More sector news : Ambulance & Emergency Services
Advertisement
Financials ($)
Sales 2016 210 M
EBIT 2016 -45,4 M
Net income 2016 35,1 M
Debt 2016 19,0 M
Yield 2016 -
P/E ratio 2016 4,09
P/E ratio 2017
EV / Sales 2016 1,27x
EV / Sales 2017 0,69x
Capitalization 249 M
More Financials
Chart ACCRETIVE HEALTH, INC.
Duration : Period :
Accretive Health, Inc. Technical Analysis Chart | US00438V1035 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 3,75 $
Spread / Average Target 61%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Gerard Flanagan President, Chief Executive Officer & Director
Steve J. Shulman Chairman
Christopher Simon Ricaurte Chief Financial Officer & Treasurer
Alex J. Mandl Independent Director
Charles J. Ditkoff Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACCRETIVE HEALTH, INC.-12.68%249
FRESENIUS SE & CO KGAA1.53%39 898
HCA HOLDINGS INC4.36%26 445
FRESENIUS MEDICAL CARE..-6.56%24 455
LABORATORY CORP. OF AM..1.30%12 901
DAVITA INC-8.03%12 655
More Results